Congenital myasthenic syndrome (COLQ)

Overview

Congenital Myasthenic Syndrome (CMS) refers to a group of inherited conditions that cause muscle weakness. Specifically, CMS due to COLQ variants affects the neuromuscular junction, which is the specialised area where nerve cells communicate with muscle cells. This communication relies on chemical signals called neurotransmitters, and in CMS (COLQ), this process is disrupted [PMID:24646700].

The condition is present from birth or early childhood, though symptoms can sometimes develop later. The severity of muscle weakness can vary significantly between individuals. While specific prevalence figures for COLQ-related CMS in the UK are not well established, it is considered a rare condition overall.

Symptoms & clinical features

Symptoms of Congenital Myasthenic Syndrome (COLQ) often include muscle weakness that can be generalised or affect specific muscle groups. In infants, this may present as 'floppiness' (hypotonia), difficulties with feeding, a weak cry, and breathing problems, sometimes requiring respiratory support [PMID:19020986]. Eyelid drooping (ptosis) and limited eye movements (ophthalmoplegia) are also common.

As children grow, they may experience problems with walking, running, or climbing stairs due to leg muscle weakness. Fine motor skills, such as writing or buttoning clothes, can also be affected. Symptoms may worsen during periods of exertion, illness, or exposure to cold temperatures. In some cases, severe muscle weakness can lead to episodes of respiratory distress, which requires urgent medical attention.

Video: Genetics 101

Affected organs

Congenital Myasthenic Syndrome (COLQ) primarily affects the voluntary muscles throughout the body. This includes the skeletal muscles responsible for movement, such as those in the limbs, trunk, and neck. The muscles controlling eye movements and eyelid opening are also frequently involved.

Critically, the respiratory muscles, important for breathing, can be affected, potentially leading to breathing difficulties and crises. Muscles involved in chewing and swallowing can also be weak, causing feeding issues and an increased risk of aspiration (food or liquid entering the airway).

Brain

Central nervous system involvement

Cellular impact

Mechanism at cellular level

Risks & severity

The severity of Congenital Myasthenic Syndrome (COLQ) can range from mild forms, with manageable muscle weakness, to severe presentations that may include life-threatening breathing difficulties. The age of onset typically occurs at or shortly after birth, or during early childhood. Some individuals may experience fluctuating symptoms, with periods of greater weakness. Respiratory crises, where breathing becomes severely compromised, are a significant risk for some affected individuals and require prompt medical intervention.

Long-term prognosis varies; some individuals learn to manage their symptoms effectively, while others may experience ongoing challenges with mobility and respiratory function. Regular monitoring and tailored management strategies are important for improving quality of life and reducing potential complications.

Genetic causes

Congenital Myasthenic Syndrome (COLQ) is caused by pathogenic variants in the COLQ gene. This gene provides instructions for making a protein that is crucial for the normal function of the neuromuscular junction [PMID:22080344]. Specifically, the COLQ protein is responsible for anchoring acetylcholinesterase, an enzyme, to the muscle cell membrane.

Acetylcholinesterase plays a key role in clearing the neurotransmitter acetylcholine from the neuromuscular junction after it has transmitted a signal. By breaking down acetylcholine rapidly, this enzyme allows the muscle to relax and prepare for the next signal. When the COLQ protein is altered due to a genetic variant, acetylcholinesterase may not be properly anchored or may be less effective, leading to a build-up of acetylcholine. This disruption interferes with the precise control of muscle contraction and relaxation, resulting in the characteristic muscle weakness seen in CMS (COLQ).

• COLQ
  collagen like tail subunit of asymmetric acetylcholinesterase
  The COLQ gene provides instructions for the acetylcholinesterase collagenic tail peptide, a protein crucial for proper function of the neuromuscular junction.

Inheritance pattern

Congenital Myasthenic Syndrome (COLQ) is inherited in an autosomal recessive pattern. This means that a person must inherit two altered copies of the COLQ gene, one from each parent, to develop the condition.

Individuals who inherit only one altered copy of the COLQ gene are called carriers. Carriers typically do not show any symptoms of the condition themselves because their other unaffected copy of the gene can compensate. If two carriers have a child together, there is a 25% (1 in 4) chance with each pregnancy that the child will inherit two altered copies of the gene and develop CMS (COLQ). There is a 50% (2 in 4) chance the child will be a carrier, and a 25% (1 in 4) chance the child will inherit two working copies of the gene and not be a carrier or have the condition.

Diagnosis & testing

Diagnosing Congenital Myasthenic Syndrome (COLQ) typically involves a combination of clinical assessment and genetic testing. A medical professional will evaluate symptoms such as muscle weakness, fatigue, and breathing difficulties. Electrophysiological studies, such as electromyography (EMG) or nerve conduction studies, may also be used to assess nerve and muscle function.

Confirmation of a diagnosis usually involves genetic testing to identify pathogenic variants within the COLQ gene. This testing is often performed through the NHS Genomic Medicine Service, typically following a referral from a neurologist or clinical geneticist. The relevant NHS R-code for testing for neuromuscular disorders, which includes CMS, would be used. Genetic counsellors can provide support and information regarding testing options and results.

Management & lifestyle

Management for Congenital Myasthenic Syndrome (COLQ) focuses on alleviating symptoms and preventing complications. Depending on the specific variant and the individual's response, medications such as acetylcholinesterase inhibitors may be used to improve muscle strength, although their effectiveness can vary significantly in COLQ-related CMS [PMID:19020986]. In some cases, specific types of therapies, such as the use of adrenergic agonists, may be considered.

Symptomatic management often includes supportive care, such as respiratory support if breathing is affected, and nutritional support for feeding difficulties. Physical and occupational therapy can help maintain muscle strength and improve daily function. Regular monitoring by a multidisciplinary team, typically including neurologists, respiratory specialists, and genetic counsellors, is crucial within the NHS pathway to adapt care as needed. Genetic counsellors can also help families understand the condition and its inheritance.

UK care pathway

In the UK, individuals suspected of having a genetic condition like Congenital Myasthenic Syndrome (COLQ) would typically be referred by their GP or a specialist to a clinical genetics service. This service, part of the NHS Genomic Medicine Service, can arrange for comprehensive genetic counselling and testing. Genetic testing relating to neuromuscular disorders, including CMS, falls under specific NHS R-codes, ensuring a standardised diagnostic approach. Clinical geneticists and genetic counsellors provide essential support, guiding families through diagnostic processes and discussing the implications of genetic results for both the affected individual and broader family members.

Related conditions

When considering conditions with similar symptoms to Congenital Myasthenic Syndrome (COLQ), other forms of CMS caused by variants in different genes are key. These other CMS types also present with varying degrees of muscle weakness but involve different genetic and molecular mechanisms at the neuromuscular junction. Additionally, acquired myasthenia gravis, an autoimmune condition, can present with similar fluctuating muscle weakness, though its cause is different. Neuromuscular disorders that involve generalised muscle weakness, such as certain muscular dystrophies or spinal muscular atrophy, might also be considered in a differential diagnosis, requiring careful clinical and genetic distinction.

Frequently asked questions